1. Home
  2. MLYS vs INVX Comparison

MLYS vs INVX Comparison

Compare MLYS & INVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • INVX
  • Stock Information
  • Founded
  • MLYS 2019
  • INVX 2024
  • Country
  • MLYS United States
  • INVX United States
  • Employees
  • MLYS N/A
  • INVX N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • INVX
  • Sector
  • MLYS Health Care
  • INVX
  • Exchange
  • MLYS Nasdaq
  • INVX NYSE
  • Market Cap
  • MLYS 893.0M
  • INVX 954.4M
  • IPO Year
  • MLYS 2023
  • INVX N/A
  • Fundamental
  • Price
  • MLYS $14.66
  • INVX $17.93
  • Analyst Decision
  • MLYS Strong Buy
  • INVX Sell
  • Analyst Count
  • MLYS 3
  • INVX 1
  • Target Price
  • MLYS $27.00
  • INVX $16.00
  • AVG Volume (30 Days)
  • MLYS 2.0M
  • INVX 343.6K
  • Earning Date
  • MLYS 05-08-2025
  • INVX 05-11-2025
  • Dividend Yield
  • MLYS N/A
  • INVX N/A
  • EPS Growth
  • MLYS N/A
  • INVX 20.96
  • EPS
  • MLYS N/A
  • INVX 2.77
  • Revenue
  • MLYS N/A
  • INVX $660,803,000.00
  • Revenue This Year
  • MLYS N/A
  • INVX N/A
  • Revenue Next Year
  • MLYS N/A
  • INVX $6.15
  • P/E Ratio
  • MLYS N/A
  • INVX $6.47
  • Revenue Growth
  • MLYS N/A
  • INVX 18.95
  • 52 Week Low
  • MLYS $8.24
  • INVX $12.54
  • 52 Week High
  • MLYS $18.38
  • INVX $24.09
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 56.01
  • INVX N/A
  • Support Level
  • MLYS $16.15
  • INVX N/A
  • Resistance Level
  • MLYS $17.21
  • INVX N/A
  • Average True Range (ATR)
  • MLYS 1.30
  • INVX 0.00
  • MACD
  • MLYS -0.03
  • INVX 0.00
  • Stochastic Oscillator
  • MLYS 36.19
  • INVX 0.00

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

About INVX INNOVEX INTERNATIONAL INC

Innovex International Inc designs, manufactures, and installs mission-critical drilling & deployment, well construction, completion, production, and fishing & intervention solutions to support upstream onshore and offshore activities worldwide. Its comprehensive portfolio extends throughout the lifecycle of the well; and innovative product integration ensures seamless transitions from one well phase to the next, driving efficiency, lowering cost, and reducing the rig site service footprint for the customer. With locations throughout North America, Latin America, Europe, the Middle East, and Asia, The team is readily available with technical expertise, conventional and innovative technologies, and ever-present customer service.

Share on Social Networks: